Genetic Abnormalities in ALL by Bendari, Mounia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books
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Abstract
Acute lymphoblastic leukemia (ALL), can be defined by a family of genetically 
heterogeneous lymphoid neoplasms derived from B- and T-lymphoid progenitors. 
ALL constitutes the most common childhood cancer, due to an overproduction 
of immature lymphoid hematopoietic cells. Genetic analyzes currently provides 
important information for classifying patients into prognostic groups, genetic 
analysis also helps to understand the mechanisms of relapse, pharmacogenetics and 
the development of new potential therapeutic targets, which should help to further 
improve the results of leukemia. In fact, the new techniques in molecular cytoge-
netic permits to identify new cryptic abnormalities, these discoveries have led to 
the development of new therapeutic protocols. The role of cytogenetic analysis is 
crucial on ALL patient’s management. Karyotyping coupled with FISH analysis 
identifies recurrent chromosomal abnormalities in ALL, many of these abnormali-
ties have prognostic and treatment impact. This chapter summarizes chromosomal 
abnormalities that are common and classify ALL according to the World Health 
Organization (WHO) classifications (2016 revision). We will present the main 
genetic modifications recently identified as well as the sequence mutations which 
have helped in the elucidation of the pathogenesis of ALL.
Keywords: Acute lymphoblastic leukemia, World Health Organization classification, 
cytogenetic analysis, FISH analysis
1. Introduction
Acute lymphoblastic leukemias (ALL) are clonal proliferations of immature cells 
involved in B (LAL-B) or T (LAL-T) lymphoid differentiation and blocked at an 
early stage of differentiation. The ALL is the most frequent childhood malignancy. 
In multiple studies dating back more than 50 years, both B-cell ALL and T-cell ALL 
are associated with characteristic and recurrent cytogenetic changes [1, 2]. They 
had a great value for diagnosis, risk stratification, disease monitoring and treatment 
selection. The conventional cytogenetics techniques have experienced significant 
advancement into molecular cytogenetics technologies. These recent advancements 
have largely overcome the limitations of conventional cytogenetics techniques. 
Fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe 
amplification (MLPA), array comparative genomic hybridization (aCGH) and 






Conventional banded karyotyping for the detection and prognosis of genetic 
diagnosis is considered as the gold standard. It has been used to analyze genome 
modifications that include both genome gains and losses, as well as rearrangements 
within and between chromosomes [5]. Conventional single cell and metaphase 
cytogenetics are important in tumor genetics for disease control, tumor staging, 
and research purposes to recognize chromosomal regions containing genes and 
proto-oncogeneses of putative tumor suppressors [6].
2.2 Fluorescence in situ hybridization (FISH)
Fluorescence in situ hybridization (FISH) is a technique for determining com-
plex DNA sequences as well as the number and structure of chromosomes. The 
method is focused on the use of fluorescent probes that can recognize specific DNA 
sequences. FISH is a technique for detecting genetic defects in embryos that is fast 
and sensitive. Targeting and denaturing DNA fixed in cells, nuclei, or metaphase 
chromosomes on the surface of the slide is the basis of the FISH analysis. Next, after 
its denaturation, a complementary single-stranded DNA sequence probe will pre-
cisely re-anneal double-stranded DNA (hybrid) molecules during the hybridization 
reaction. Probe DNA molecules are labeled enzymatically with modified nucleo-
tides. They are DNA molecules designated hapten-labeled (indirect FISH) and 
fluorescent-labeled (direct FISH). An antifade solution containing 4′,6-diamidino-2 
phenylindole is added to the slide after the removal of unbound single-stranded 
DNA and nonspecifically bound DNA from the slide by posthybridization washing. 
Using epifluorescence microscopes with specialized filters for detecting fluoro-
chromes, FISH signals are observed. The signal is captured by a charge-coupled 
system camera, and the fluorescent signals are then quantified [7, 8].
2.3 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) is a fast and cheap technique used to “amplify” 
small segments of DNA by copying them. Because significant amounts of a sample 
of DNA are needed for molecular and genetic analysis, without PCR amplifica-
tion, studies of isolated pieces of DNA are almost impossible. The PCR method 
is based on a cell’s natural processes for replicating a new DNA strand. For PCR, 
only a few biological ingredients are needed. The template DNA—that is, the DNA 
that contains the region to be copied, such as a gene—is an essential component. A 
prototype can be as small as one DNA molecule. The sequence of two short regions 
of nucleotides (DNA subunits) at either end of the region of interest is all that is 
needed for this fragment to be replicated. The primers bind to the template at their 
complementary sites, or anneal, and serve as the starting point for copying. The 
replication of the desired intervening sequence is achieved when DNA synthesis at 
one primer is guided toward the other. Free nucleotides and a DNA polymerase, an 
enzyme that builds new DNA strands by sequentially adding on free nucleotides 
according to the template’s instructions, are also needed.
2.4 Next-generation sequencing (NGS)
NGS requires sequencing of millions of DNA molecules concurrently to produce 
sequence reads. In order to detect small insertions/deletions (indels) and structural 
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variants (SVs) of 450 bp, sequence reads are aligned with the reference genome 
and base variants. Overall, NGS has the potential to generate up to one billion short 
reads per instrument cycle, an immense amount of data cheaply.
3. Chromosomal and molecular abnormalities associated with ALL-B
60–80% of patients with ALL have abnormalities in chromosome number or 
structural rearrangements (translocations), whereas the remaining 20–40% have 
normal karyotype [9, 10]. Besides those with a normal karyotype, t(9;22)(q34,q11); 
BCR/ABL (BCR-ABL1), t(12;21)(p13;q22);TEL/AML1 (ETV6-RUNX1), t(4;11) 
(q21;q23); MLL/AF4 (KMT2A/AFF1), t(1;19)(q23;p13); E2A/PBX1 (TCF3-PBX1), 
are the most common cytogenetic subtypes in ALL [10–12].
3.1 Structural chromosomal abnormalities
3.1.1 The t(9;22)(q34;q11.2)(BCR-ABL1)
The BCR/ABL1 or Philadelphia (Ph) chromosome is a t(9;22) product that fuses 
the chromosome 9 Abelson kinase gene (ABL1) with the chromosome 22 breakpoint 
cluster region (BCR) that expresses the fusion protein BCR-ABL1: a constitutively 
active tyrosine kinase. The breakpoint occurs between exons 1 and 2 (e1 and e2) of 
the BCR gene in the minor breakpoint cluster region, m-BCR, in the majority of Ph 
positive ALL patients, and between exons 1 and 2 of the ABL gene in the majority of 
Ph positive ALL patients (e1a2). This results in the development of a 7-kb mRNA and 
the expression of the p190 protein [13]. This transcribes an 8.5 kb mRNA that codes 
for a chimeric p210 protein [14]. The Philadelphia chromosome is the most impor-
tant cytogenetic abnormality. It is seen in 3% of pediatric patients, and almost 25% 
of adults, and rises with age, reflecting about half of the cases of patients older than 
60 years of age, and although historically associated with poor prognosis, results 
have been markedly improved with the use of tyrosine kinase inhibitors (TKIs) [15].
3.1.2 The t(12;21)(p13;q22)(ETV6-RUNX1)
The most prevalent translocation in childhood acute lymphoblastic leukemia is 
TEL-AML1 gene fusion, induced by t(12;21) (p12;q22). However, this anomaly is 
rare among adults. The translocation of t(12;21) is cryptic by normal G-banding 
and includes FISH examination for cytogenetic detection [16]. ETV6-RUNX1 
patients were thought to have a good prognosis at first, and they were associated 
with favorable risk factors including female gender, young age, low white cell count, 
and CD10+ immunophenotype [17]. However, some studies found no gain for 
ETV6-RUNX1 patients [18], while others found a high incidence of gene fusion in 
relapse patients and a predilection for late relapse [19, 20]. However, it is now clear 
that the initial optimism was justified. Almost every major clinical trial group in 
the world has confirmed that children with the ETV6-RUNX1 fusion have excel-
lent overall survival and very low relapse rates [21, 22], and the presence of added 
cytogenetic or molecular abnormalities does not modify this good prognosis.
3.1.3 The KMT2A (MLL) Gene Rearrangements (11q23)
A transcriptional coactivator with methyltransferase activity encodes the gene 
KMT2A. The rearrangements result in the fusion of the 5′ portion of KMT2A, 
including the methyltransferase domain, to the 3′ region of the partner genes. 
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KMT2A (MLL) rearrangements, particularly the translocation of t(4;11)(q21;q23), 
are most common in infants (<1 year of age) and are associated with poor outcomes 
[23, 24]. The t(4;11)(q21;q23) can be detected by conventional cytogenetics, FISH, 
RT-PCR, or Southern blot techniques. Overall, ALL with MLL rearrangement have 
an unfavorable prognosis.
3.1.4 The t(1;19)(q23;P13), TCF3-PBX1
The translocation t(1;19)(q23;p13) is the result of the fusion of the PBX1 gene at 
1q23 with the TCF3 (E2A) gene at 19p13.3. This translocation occurs in approximately 
5–6% of childhood and adult B-cell precursor (BCP) ALLs [25, 26]. The transloca-
tion t(1.19) appears in balanced form (presence of two derived chromosome) or 
more often in unbalanced form with the derivative chromosome 19: (der (19)t(1.19)
(q23;p13)). TCF3-PBX1 patients usually have a pre-B immunophenotype that 
expresses cytoplasmic μ [27]. It’s one of the few genetic disorders that doesn’t seem to 
increase in frequency with age. Originally considered a high-risk subtype of ALL, it 
is now associated with a favorable outcome with contemporary treatment, although 
some studies have indicated that it has an independent risk factor for CNS relapse [28].
3.1.5 IKZF1(7p12) deletion or mutations
The IKZF1 gene is located on the 7p12.2 chromosome band, consists of 8 exons, 
and codes for the transcription factor IKAROS with key regulatory functions in 
lymphopoiesis [29, 30]. IKAROS harbors 6 fingers zinc. Four of these are located in 
the DNA-binding domain encoded by exons 4 to 6 and are important for the tumor 
suppressor function of IKAROS to be preserved. Exon 8 encodes the remaining 
2 zinc fingers and mediates IKAROS dimerization either as a homodimer or with 
other transcription factors in its family [29, 31]. The deletions of this gene, are very 
frequently associated with the BCR-ABL1 fusion in the development of ALL of the 
B line. These deletions result in haploinsufficiency by partial or total deletion. it 
seems that these deletions represent an independent risk of relapse.
3.1.6 CRLF2 rearrangement (IGH-CRLF2; P2RY8-CRLF2)
CRLF2 encodes cytokine receptor-like factor 2, also known as the thymic 
stromal-derived lymphopoietin receptor (TSLPR), wich forms an heterodimeric 
receptor with the interleukin-7 receptor a chain (IL7Ra) for thymic stromal lym-
phopoietin (TSLP). CRLF2 is deregulated by translocation into the immunoglobulin 
heavy chain locus (IGH-CRLF2); focal deletion upstream of CRLF2, resulting 
in P2RY8-CRLF2 fusion; and less often, CRLF2 point mutations (F232C) [32]. 
In Ph-like and Down syndrome-related ALL, CRLF2 rearrangements are most 
common and are age dependent, with P2RY8-CRLF2 associated with young age 
and IGH-CRLF2 associated with older age and Hispanic ancestry [33, 34]. Most 
CRLF2-rearranged ALLs have additional JAK–STAT or Ras signaling alterations, 
particularly activating JAK1 or JAK2 mutations, FLT3 and IL7R sequence mutations, 
SH2B3 deletions, TSLP rearrangements, and Ras mutations [35–37]. CRLF2 rear-
rangements have been associated with poor prognosis in most studies, especially in 
cases of concomitant IKZF1 alteration [38, 39].
3.1.7 Intrachromosomal amplification of chromosome 21 (iAMP21)
Intrachromosomal amplification of chromosome 21 or iAMP21 is defined 
as the presence of three or more additional copies of RUNX1 on a structurally 
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abnormal chromosome 21. The iAMP21 chromosome is often initially detected by 
ETV6 - RUNX1 FISH analysis [40, 41]. It affects about 2–5% of B-cell precursor 
acute lymphoblastic leukemia pediatric patients [42, 43]. Patients with iAMP21 are 
usually between the ages of 7 and 13, with a median age of 10 [44]. It is particularly 
uncommon in children under the age of five and in people over the age of twenty. 
Complex intrachromosomal amplification of chromosome 21 is most common in 
older children and the poor prognosis is improved by high-risk treatment. Accurate 
identification of this abnormality is considered to be extremely necessary in 
 determining the best course of treatment.
3.1.8  The Philadelphia Chromosome – like Acute Lymphoblastic Leukemia  
(Ph-like ALL)
Ph-like, or BCR-ABL1-like ALL is characterized by a leukemic cell transcrip-
tional profile similar to Ph + ALL but lack the BCR-ABL1 fusion gene [45, 46]. 
Ph-like ALL is vary heterogeneous in the altered genes and the form (rearrange-
ments, mutations, or deletions) of alterations that result in the activated tyrosine 
kinase or cytokine receptor signaling characteristic of this subtype of ALL [46]. 
However, these fall into four main groups: (1) Alterations driving JAK–STAT 
signaling, most commonly rearrangements of CRLF2 (IGH-CRLF2, P2RY8-CRLF2, 
CRLF2 F232C), and less commonly, rearrangements of JAK2, EPOR, or TYK2, 
and mutations/deletions of IL7R, SH2B3, JAK1, JAK3, TYK2, IL2RB); (2) fusions 
involving ABL-class genes (ABL1, ABL2, CSF1R, LYN, PDGFRA, PDGFRB); (3) 
mutations activating Ras signaling (NRAS, KRAS, PTPN11); and (4) less common 
fusions (FLT3, FGFR1, NTRK3) [35, 36, 47]. Ph-like is associated with high-risk 
clinical characteristics, poor response to induction chemotherapy, elevated levels of 
minimal residual disease (MRD), and/or poor survival [48].
3.2 ALL with number anomalies
3.2.1 Hyperdiploidy
Hyperdiploidy is the most prevalent recurrent abnormality in childhood B-ALL. 
In the World Health Organization classification of tumors of hematopoietic and 
lymphoid tissues, hyperdiploidy in B-lymphoblastic leukemia (B-ALL), charac-
terized by the presence of 51–65 chromosomes, has been identified as a distinct 
subtype of B-ALL [49]. In hyperdiploidy, numerical chromosomal gains are non-
random, with additional copies (usually trisomies) of chromosomes 21, X, 14, and 
4 most commonly found in pediatric patients [50]. Despite the presence of non-
specific structural abnormalities, the extra chromosomes are still normal copies of 
chromosomes. There is a poor understanding of the mechanism involved in induc-
ing hyperdiploidy and its role in leukaemogenesis. Hyperdiploid B-ALL comprises 
approximately 25–30% of pediatric B-ALL cases [51]; and is often associated with 
a favorable prognosis with a cure rate greater than 90%, especially when hyperdip-
loidy is associated with trisomies of chromosomes 4 and 10 [52–54].
3.2.2 Hypodiploidy
Hypodiploidy, characterized by less than 44 chromosomes is less frequent than 
hyperdiploid ALL. Three cytogenetic subgroups of hypodiploidy were defined: 
near haploidy, with 24–31 chromosomes; low hypodiploid, with 32–39 chromo-
somes; and high hypodiploid, with 40–43 chromosomes [55]. Near-haploidy 
patients showed common chromosomal gains, rare structural abnormalities and a 
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co-incident doubled hyperdiploid population [56–58]. Low hypodiploidy karyo-
types are usually monosomic for chromosomes 3, 7, 15, 16, 17, and disomic for 
chromosomes 1, 6, 11, and 18. In this subgroup, the phenomenon of doubling-up 
occurs, and sub-clones with near-triploid karyotypes are common. Furthermore, 
evidence indicates that in near-haploid situations, cytogenetic research is more 
likely to show only the doubled-up clone. Overall Hypodiploid acute lymphoblastic 
leukemia (ALL) has been associated with a dismal prognosis [59, 60].
4. Chromosomal and molecular abnormalities associated with ALL-T
T-cell acute lymphoblastic leukemia (T-ALL) is a leukemia that develops when 
there is an accumulation of genomic lesions that impair T-cell growth. T-ALL is cor-
related with a lot of genetic diversity. The accumulation of a variety of genetic and 
epigenetic defects leads to leukemic transformation [61]. As a result of excessive 
neoplastic cell proliferation, they cause disorders of cell differentiation, apoptosis, 
oncogene activation, and suppressor inhibition. The first genetic abnormalities in 
T-ALL patients were chromosome aberrations. Except for tetraploidy, which occurs 
in around 5% of cases, numerical changes are uncommon and have little prognostic 
significance.
The identification of chromosomal anomalies, such as 9p deletions that result in 
CDKN2A (p16) and CDKN2B (p15) inactivation, and translocations affecting T-cell 
receptor genes, has been crucial in gaining an understanding of the genetic defects 
present in T-ALL.
The proportion of cytogenetically normal cases at diagnosis is higher in T-ALL 
than in B-ALL, with about 50 percent of patients with T-ALL possessing a normal 
karyotype. Approximately one-third of T-ALL patients have a translocation involv-
ing one of the T-cell receptor genes (TCR), with a breakpoint at 14q11 (TCRA/
TCRD) or 7q34 (TCRB), juxtaposing the T-cell receptor genes to pivotal transcrip-
tion factor genes, such as TAL1, TAL2, LYL1, OLIG2, LMO1, LMO2, TLX1 (HOX11), 
TLX3 (HOX11L2), NKX2–1, NKX2–2, NKX2–5, HOXA genes, MYC, and MYB. In 
the adult population, the translocation t(10;14)(q24;q11.2), which results in over-
expression of the TLX1 (HOX11) gene, is the most common and is associated with a 
favorable outcome [62, 63]. In addition, T-ALLs can contain cryptic rearrangements 
of ABL1 that may be amenable to TKI therapy. In general, studies of gene expression 
profiling have helped to classify T-ALL into molecular subgroups characterized by 
distinct signatures of gene expression and aberrant activation of specific oncogenes 
of the T-ALL transcription factor, including MEF2C, HOXA, TLX1, NKX2.1, TLX3, 
TAL1, LMO1, and LMO2 [41, 64].
5. Conclusion
Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer. 
However, conventional cytogenetic and molecular analyses fail to identify clonal 
driver alterations in approximately 25% of ALL in children and the majority of 
cases in adults but when they are present, they have a crucial role in the manage-
ment of ALL patients. Recent advancements in gene expression profiling and 
genome-wide sequencing have revolutionized our understanding of ALL patho-
genesis over the last years. As defined in this review, the accumulation of results has 
restructured ALL genetic classifications. Overall, we expect that research over the 
next decade can thoroughly define the genomic of ALL across all generations and 
refine the therapeutic algorithm to be more targeted and individualized.
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